The World Hematology Month is a golden opportunity to raise awareness of the importance of medical examination
Cairo witnessed a press conference under the title “See what is not found” held by Janssen Egypt on the occasion of the month of awareness of blood tumors, in the presence of a patient with multiple myeloma, Dr. Raafat Abdel-Fattah, Professor of Hematology and Bone Marrow Transplantation at the National Cancer Institute, Cairo University, and Dr. Mahmoud Salah Abdel Salam, Consultant and Head of Department Diseases and tumors of the blood and bone marrow transplantation at the International Medical Center and Dr. Ramez Mohsen, CEO of Janssen Company for Egypt, North East Africa and Jordan.
The month of September of each year witnesses a huge activity in raising awareness of these invisible tumors, with the aim of spreading community awareness and highlighting the importance of early medical examination and accurate diagnosis. Therefore, Janssen Egypt – the pharmaceutical arm of Johnson & Johnson International Company – and the pioneer in the field of advanced treatments for cancer, launched And hematomas slogan “See what is not cured”, to raise awareness of blood tumors such as multiple myeloma and chronic lymphocytic leukemia.
At first, one of the “multiple myeloma” patients expressed her happiness at highlighting blood tumors, especially multiple myeloma, noting that it has been part of her message since 2018, when she launched the psychological support initiative for “myeloma” patients because it is a chronic disease, and chronic tumors are not easy and need to be repeated. Psychological rehabilitation of the patient, wondering… How can a person live the rest of his life taking chemotherapy! While she thanked Janssen Egypt for its continuous and effective efforts in raising awareness to support patients with these tumors under the slogan “See what is not cured”.
She explained that she has been a patient of “multiple myeloma” since she was 39 years old, and that her journey was full of different stages in terms of feeling positive and negative, pointing out that this is normal for tumor patients, and despite that, she was able to help herself by overcoming negative feelings, pain, and turning it into energy. Positivity enabled her to learn new things, and also revealed to her her talents such as writing and drawing, as she was able to achieve many things that she would not have imagined that she would do as a patient of hematological tumors.
It also advises patients not to neglect the appearance of abnormal symptoms on them, such as low hemoglobin, which may be one of the most important indicators of the disease.
She added that the journey of pain began for her on November 5, 2011, and lasted three months, then she was diagnosed and this is considered an early diagnosis, pointing out that many patients need much longer time to be diagnosed, which leads to a deterioration of the condition, noting the importance of early diagnosis until The disease does not affect the body’s organs, and adherence to treatment is as important as patients suffering from chronic diseases such as diabetes and pressure, who continue to take treatment according to the doctors’ instructions, and in turn, I would like to advise all myeloma patients to adhere to therapeutic doses, and continuous follow-up with the treating physician She also pointed out the importance of psychiatry and psychological support from those close to her, as they formed lifelines for her experience, and demanded not to feel embarrassed about seeking psychological support.
For his part, Dr. Raafat Abdel-Fattah, Professor of Hematology and Bone Marrow Transplantation at the National Cancer Institute, Cairo University, confirmed that blood tumors represent about 10% of all cancers diagnosed annually, and multiple myeloma represents about 10% of all blood diseases, and the incidence of multiple myeloma among men is higher than Women 1 & 2 He explained that the multiple myeloma patient often goes to the internal medicine, orthopedic, or kidney doctor, because the symptoms begin with pain in the bones, and can reach fractures, in addition to failure in kidney functions, and therefore we call on patients who suffer from symptoms such as Extreme exhaustion, which represents anemia, or symptoms of bone pain, to go to the doctor for a medical examination, and in the case of severe exhaustion, to go to a hematologist, and here comes the importance of modern advanced treatments in the treatment of multiple myeloma that leads to a high response to the patient, 2 Continuity of treatment – according to International protocols – lead to the continuity of a good response, and he stressed that providing these treatments in a timely manner to patients guarantees them a better life, especially since the disease has become observed among young people in recent times. They represent the country’s national wealth, and this affects their working and personal lives, which affects their productivity and, consequently, the state’s economy.
He explained that the state, in recent years, has worked to provide the latest treatments for multiple myeloma patients, which has led to a major breakthrough in controlling the disease, and the patient has been living longer and with a good quality of life.
Dr. Mahmoud Salah Abdel Salam, Consultant and Head of the Department of Hematology, Oncology and Bone Marrow Transplantation at the World Medical Center indicated that chronic lymphocytic leukemia is one of the most common types, and in 2021 in the United States of America, about 20 thousand cases of chronic lymphocytic leukemia were monitored, while 4 thousand cases are monitored. Death annually 11, and the disease is characterized by the accumulation of white blood cells lymphatic in the blood, bone marrow, and lymphatic tissues, and the symptoms of the disease are an increase in white blood cells and lymphocytes, and may be accompanied by anemia or a deficiency in blood platelets, and it may come with an enlargement of the lymph nodes or spleen, and a high temperature Weight loss, general weakness.
He added that the diagnosis of chronic lymphocytic leukemia depends on a set of laboratory tests to confirm the diagnosis through advanced genetic analyzes, which must be conducted early when infected because it also shows the severity and severity of the disease, which determines the appropriate type of treatment. 10 He said that the treatment of chronic lymphocytic leukemia was based on chemotherapy only, and its results were modest, pointing to the great development in medicines, pointing to the emergence of immunotherapy, which targets cancer cells only, and thus the effectiveness has become high and its side effects are few. The 5-year survival rates have also grown to 70% due to scientific development.
He pointed out that there are some cases accompanied by genetic mutations of the disease that do not respond to chemotherapy or immunotherapy or both, and therefore the patient must take one of the modern treatments, and once the genetic analysis is proven, treatment must be started through the new targeted therapy, to achieve good results.
He explained that recent years have witnessed a huge development in the health system in Egypt, where accurate diagnosis is available for patients, and all types of treatments for chronic lymphocytic leukemia are available, so patients with blood tumors in Egypt are treated according to international standards. After the use of modern protocols consisting of targeted drugs and immunotherapy, a major leap occurred in the results of disease control, and the patient lived longer with a good quality of life.
For his part, Dr. Ramez Mohsen, CEO of Janssen for Egypt, North East Africa and Jordan – one of Johnson & Johnson’s global companies – explained that the company, being a pioneer in the field of oncology and hematological tumors treatments for more than thirty years, feels proud of Janssen’s active participation in the activities of the international month. For hematological tumors, the company believes in the right of the Egyptian patient to receive good health care and to provide modern treatments in a timely manner and for an appropriate period in accordance with international protocols. He also praised the increasing interest of the Egyptian state in the Egyptian patient’s health and placing the health file at the top of its priorities, as studies have proven that modern treatments lead to a decrease in the number of tumor-related deaths and a noticeable improvement in the quality of life of patients.
He also added Dr. Ramez said that in the recent period there has been a great leap in terms of innovation and development in scientific research in cancer and blood tumors, which has led to a remarkable difference in the lives of patients8, especially after the great development in targeted therapies, or what is known as precision medicine. However, cancer is still the second leading cause of death and has the largest economic impact in the world8. Despite that, spending on it – which is in fact an investment – is not commensurate with the disease related to the disease, so the company is doing its best to provide modern and advanced treatments to patients so as not to be deprived The Egyptian patient is so right.
In the context of providing advanced solutions to patients through scientific research, Janssen Egypt has started sponsoring an important genetic analysis for patients with blood tumors.
The World Hematology Month is a golden opportunity to raise awareness of the importance of medical examination
Cairo witnessed a press conference under the title “See what is not found” held by Janssen Egypt on the occasion of the month of awareness of blood tumors, in the presence of a patient with multiple myeloma, Dr. Raafat Abdel-Fattah, Professor of Hematology and Bone Marrow Transplantation at the National Cancer Institute, Cairo University, and Dr. Mahmoud Salah Abdel Salam, Consultant and Head of Department Diseases and tumors of the blood and bone marrow transplantation at the International Medical Center and Dr. Ramez Mohsen, CEO of Janssen Company for Egypt, North East Africa and Jordan.
The month of September of each year witnesses a huge activity in raising awareness of these invisible tumors, with the aim of spreading community awareness and highlighting the importance of early medical examination and accurate diagnosis. Therefore, Janssen Egypt – the pharmaceutical arm of Johnson & Johnson International Company – and the pioneer in the field of advanced treatments for cancer, launched And hematomas slogan “See what is not cured”, to raise awareness of blood tumors such as multiple myeloma and chronic lymphocytic leukemia.
At first, one of the “multiple myeloma” patients expressed her happiness at highlighting blood tumors, especially multiple myeloma, noting that it has been part of her message since 2018, when she launched the psychological support initiative for “myeloma” patients because it is a chronic disease, and chronic tumors are not easy and need to be repeated. Psychological rehabilitation of the patient, wondering… How can a person live the rest of his life taking chemotherapy! While she thanked Janssen Egypt for its continuous and effective efforts in raising awareness to support patients with these tumors under the slogan “See what is not cured”.
She explained that she has been a patient of “multiple myeloma” since she was 39 years old, and that her journey was full of different stages in terms of feeling positive and negative, pointing out that this is normal for tumor patients, and despite that, she was able to help herself by overcoming negative feelings, pain, and turning it into energy. Positivity enabled her to learn new things, and also revealed to her her talents such as writing and drawing, as she was able to achieve many things that she would not have imagined that she would do as a patient of hematological tumors.
It also advises patients not to neglect the appearance of abnormal symptoms on them, such as low hemoglobin, which may be one of the most important indicators of the disease.
She added that the journey of pain began for her on November 5, 2011, and lasted three months, then she was diagnosed and this is considered an early diagnosis, pointing out that many patients need much longer time to be diagnosed, which leads to a deterioration of the condition, noting the importance of early diagnosis until The disease does not affect the body’s organs, and adherence to treatment is as important as patients suffering from chronic diseases such as diabetes and pressure, who continue to take treatment according to the doctors’ instructions, and in turn, I would like to advise all myeloma patients to adhere to therapeutic doses, and continuous follow-up with the treating physician She also pointed out the importance of psychiatry and psychological support from those close to her, as they formed lifelines for her experience, and demanded not to feel embarrassed about seeking psychological support.
For his part, Dr. Raafat Abdel-Fattah, Professor of Hematology and Bone Marrow Transplantation at the National Cancer Institute, Cairo University, confirmed that blood tumors represent about 10% of all cancers diagnosed annually, and multiple myeloma represents about 10% of all blood diseases, and the incidence of multiple myeloma among men is higher than Women 1 & 2 He explained that the multiple myeloma patient often goes to the internal medicine, orthopedic, or kidney doctor, because the symptoms begin with pain in the bones, and can reach fractures, in addition to failure in kidney functions, and therefore we call on patients who suffer from symptoms such as Extreme exhaustion, which represents anemia, or symptoms of bone pain, to go to the doctor for a medical examination, and in the case of severe exhaustion, to go to a hematologist, and here comes the importance of modern advanced treatments in the treatment of multiple myeloma that leads to a high response to the patient, 2 Continuity of treatment – according to International protocols – lead to the continuity of a good response, and he stressed that providing these treatments in a timely manner to patients guarantees them a better life, especially since the disease has become observed among young people in recent times. They represent the country’s national wealth, and this affects their working and personal lives, which affects their productivity and, consequently, the state’s economy.
He explained that the state, in recent years, has worked to provide the latest treatments for multiple myeloma patients, which has led to a major breakthrough in controlling the disease, and the patient has been living longer and with a good quality of life.
Dr. Mahmoud Salah Abdel Salam, Consultant and Head of the Department of Hematology, Oncology and Bone Marrow Transplantation at the World Medical Center indicated that chronic lymphocytic leukemia is one of the most common types, and in 2021 in the United States of America, about 20 thousand cases of chronic lymphocytic leukemia were monitored, while 4 thousand cases are monitored. Death annually 11, and the disease is characterized by the accumulation of white blood cells lymphatic in the blood, bone marrow, and lymphatic tissues, and the symptoms of the disease are an increase in white blood cells and lymphocytes, and may be accompanied by anemia or a deficiency in blood platelets, and it may come with an enlargement of the lymph nodes or spleen, and a high temperature Weight loss, general weakness.
He added that the diagnosis of chronic lymphocytic leukemia depends on a set of laboratory tests to confirm the diagnosis through advanced genetic analyzes, which must be conducted early when infected because it also shows the severity and severity of the disease, which determines the appropriate type of treatment. 10 He said that the treatment of chronic lymphocytic leukemia was based on chemotherapy only, and its results were modest, pointing to the great development in medicines, pointing to the emergence of immunotherapy, which targets cancer cells only, and thus the effectiveness has become high and its side effects are few. The 5-year survival rates have also grown to 70% due to scientific development.
He pointed out that there are some cases accompanied by genetic mutations of the disease that do not respond to chemotherapy or immunotherapy or both, and therefore the patient must take one of the modern treatments, and once the genetic analysis is proven, treatment must be started through the new targeted therapy, to achieve good results.
He explained that recent years have witnessed a huge development in the health system in Egypt, where accurate diagnosis is available for patients, and all types of treatments for chronic lymphocytic leukemia are available, so patients with blood tumors in Egypt are treated according to international standards. After the use of modern protocols consisting of targeted drugs and immunotherapy, a major leap occurred in the results of disease control, and the patient lived longer with a good quality of life.
For his part, Dr. Ramez Mohsen, CEO of Janssen for Egypt, North East Africa and Jordan – one of Johnson & Johnson’s global companies – explained that the company, being a pioneer in the field of oncology and hematological tumors treatments for more than thirty years, feels proud of Janssen’s active participation in the activities of the international month. For hematological tumors, the company believes in the right of the Egyptian patient to receive good health care and to provide modern treatments in a timely manner and for an appropriate period in accordance with international protocols. He also praised the increasing interest of the Egyptian state in the Egyptian patient’s health and placing the health file at the top of its priorities, as studies have proven that modern treatments lead to a decrease in the number of tumor-related deaths and a noticeable improvement in the quality of life of patients.
He also added Dr. Ramez said that in the recent period there has been a great leap in terms of innovation and development in scientific research in cancer and blood tumors, which has led to a remarkable difference in the lives of patients8, especially after the great development in targeted therapies, or what is known as precision medicine. However, cancer is still the second leading cause of death and has the largest economic impact in the world8. Despite that, spending on it – which is in fact an investment – is not commensurate with the disease related to the disease, so the company is doing its best to provide modern and advanced treatments to patients so as not to be deprived The Egyptian patient is so right.
In the context of providing advanced solutions to patients through scientific research, Janssen Egypt has started sponsoring an important genetic analysis for patients with blood tumors.